Search Results 561-570 of 18316 for peptides

  1. AMBER-HFpEF: Assessment Of CK-4021586 In A Multi-Center, Blinded Evaluation Of Safety And Tolerability Results In HFpEF - Mayo Clinic

    * Participants on a glucagon-like peptide-1 (GLP-1) agonist must be on a stable dose for more than 24 weeks prior to screening with no anticipated plans to ...

  2. Publications - Karissa N. Arca, M.D. - Mayo Clinic

    Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.

  3. A Study to Assess the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Celiac Disease Patients - Mayo Clinic

    Diagnosed with celiac disease based on positive serology (eg, tissue transglutaminase IgA antibody and/or deamidated gliadin peptide IgG) and intestinal ...

  4. A Study of the Effectiveness and Safety of Lanreotide Autogel/ Depot for Patients who have Lung Neuroendocrine Tumors - Mayo Clinic

    Has been treated with Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization; Has been treated with more than one course of ...

  5. Publications - Sumera R. Ahmad, M.B.B.S. - Mayo Clinic

    Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study. Crit Care ...

  6. Cardiovascular Medicine - Doctors - Mayo Clinic

    Brain natriuretic peptide test, Heart failure, Cardiomyopathy, Pulmonary hypertension, Cardiac amyloidosis. Guy S. Reeder, M.D..

  7. Overview - Center for Regenerative Biotherapeutics - Mayo Clinic Research

    The Mayo Clinic Center for Regenerative Biotherapeutics translates new biotherapies to early-phase clinical trials with field-leading biomanufacturing ...

  8. Safety And Efficacy Of EndoBarrier In Subjects With Type 2 Diabetes Who Are Obese - Mayo Clinic

    Participation eligibility · Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis · C-peptide < 1.0 ng/mL · Previous GI surgery or abnormal ...

  9. A Multi-center Study A Single IV Infusion Of Allogeneic MPCs In Patients With Rheumatoid Arthritis And Incomplete Response To At Least One TNF Alpha Inhibitor - Mayo Clinic

    Must be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (anti-CCP3) but without extra-articular disease or severe functional limitation ...

  10. Butyrate Adjuvant Therapy for Type 1 Diabetes - Mayo Clinic

    All type 1 diabetes with C-Peptide (CPR) less than 0.5 ng/mL subjects who are > 20 and <80 years of age recruited from the Mayo Clinic Endocrinology Clinic ...